Ascentage to Start China Trials of Bcl-2 Apoptosis Candidate

Suzhou Ascentage Pharma said its novel Bcl-2 inhibitor was approved to start two China Phase Ib/II clinical trials: one in Waldenström macroglobulinemia (WM), and the other one in multiple myeloma (MM). APG-2575 is designed to treat hematologic malignancies by selectively blocking Bcl-2 to restore the normal apoptosis process in cancer cells. The candidate has started multiple trials in China and Australia . The WM Phase Ib/II trial will be a global multicenter test with centers in Australia , China and the US . More details.... Stock Symbol: (HK: 6855) Share this with colleagues: // //